Glioblastoma multiforme (GBM) is the most frequently occurring and gravest primary tumor of the CNS in adults. The development of chemoresistance to temozolomide (TMZ), the first-line chemotherapy for GBM, is an important factor contributing to poor treatment outcomes. Down-regulation of O-6-methylguanine-DNA methyltransferase (MGMT) expression in GBM cells is an attractive strategy for overcoming TMZ resistance and improving outcomes. This study revealed that the nitric oxide (NO) donor S-nitroso-N-acetylpenicillamine (SNAP) exerts antitumorigenic effects on TMZ-sensitive and TMZ-resistant (TMZ-R) glioma cells. Pretreatment with SNAP not only induced apoptosis, mitochondrial dysfunction, and hypoxia-inducing factor 1, but also resensitized TMZ-R GBM cells to TMZ through down-regulation of MGMT expression. SNAP acted principally through posttranslational modification of p53, phosphorylated N-myc downstream regulated gene 1, and MGMT protein stability in TMZ-R GBM cells. Additionally, when applied together, SNAP and TMZ enhanced the inhibition of tumor growth in vitro and in vivo. This study sheds new light on a potential strategy to overcome TMZ resistance in GBM and thus possesses the potential for prolonging survival of patients with
Glioblastoma multiforme (GBM) is the most frequently occurring and gravest primary tumor of the CNS in adults. The mean survival time is only 8-15 mo after standard treatment with surgery and chemoradiotherapy (1) . The development of chemoresistance to temozolomide (TMZ), the first-line chemotherapy for GBM, is a key factor contributing to the poor treatment outcomes (2) . TMZ induces glioma cell death through methylation injury of the DNA, often at the N-7 or O-6 position of guanine residues. However, GBM cells overcome this toxic effect of TMZ by expressing a DNA repair enzyme, O-6-methylguanine-DNA methyltransferase (MGMT). The resultant TMZresistant (TMZ-R) GBM cells play an important role in tumor recurrence. There is thus an urgent need to develop a strategy that overcomes TMZ resistance and prolongs survival time.
Down-regulation of MGMT expression is an attractive strategy for overcoming TMZ resistance and increasing the response to TMZ. Studies have shown that up-regulation of the MGMT gene is associated with several transcription factors, including hypoxia-inducing factor 1 (HIF-1)a, specificity protein 1, CCAAT enhancer binding protein, NF-kB, and activator protein 1 (3) , but that up-regulation of p53 may repress MGMT through interaction with specificity protein 1 (4) . In addition, methylation of CpG dinucleotides in the main consensus sequences of the MGMT promoter could impede attachment of the aforementioned transcription factors. Epigenetic modifications and microRNAs are also important modulators of MGMT expression at the posttranscriptional level (3) . At the post-translational level, a recent study showed that the mechanistic target of rapamycin target, N-myc downstream regulated gene 1 (NDRG1), acts as a vital mediator of resistance to alkylating chemotherapy by promoting MGMT stabilization through direct protein-protein interaction (5) . Thus, an understanding of the mechanism among transcriptional, post-transcriptional, and post-translation levels of MGMT expression is crucial for developing strategies to overcome TMZ resistance.
Nitric oxide (NO) is physiologically generated from Larginine by 3 isoforms of NOSs, including neuronal NOS, eNOS, and iNOS (6) . NO is a pleiotropic signal transducer involved in multiple essential functions in the body (7) . NO's extensive biologic activities include interactions with DNA, proteins, and inorganic molecules (e.g., oxygen and superoxide) through interruption of paired electron and prosthetic groups (e.g., heme) (8) . NO plays key roles in tumor physiology, supporting cell proliferation and survival (9) but also sensitization to chemotherapy (10) and radiotherapy (11) . Several NO donors exhibit antiproliferative activity in various cancer cell lines (12) . Those studies provide evidence that S-nitrosylation of certain proteins may exert therapeutic effects on tumor progression and responsiveness.
S-nitroso-N-acetylpenicillamine (SNAP), a tertiary S-nitrosothiol, acts as an NO donor and a potential antitumor drug. Leung et al. (10) found that SNAP could overcome cisplatin resistance in human ovarian cancer cells via p53 up-regulation and alteration of NOS. Riganti et al. (13) reported that SNAP reversed chemoresistance to doxorubicin in HT29-dx colon cancer cells by inducing tyrosine nitration of proteins associated with multidrug resistance and impeding doxorubicin efflux. SNAP also increased the radiosensitivity of murine mammary adenocarcinoma cells at suitable concentrations and exposure times (11) . In addition, Hickok et al. (14) reported that NO repressed tumor cell migration by up-regulating NDRG1, which is also associated with MGMT protein stability. These findings suggest SNAP could be used as an adjuvant treatment for cancers. However, its role in TMZ-R GBM cells has not been studied. In the present study, therefore, we examined SNAP's antitumor effects in TMZ-sensitive and TMZ-R glioma cells. Our findings indicate that SNAP resensitizes TMZ-R cells to TMZ by down-regulating MGMT expression. Moreover, the inhibitory effect on tumor growth in vitro and in vivo is better in combination of SNAP with TMZ therapies than in single-agent treatment. Thus, SNAP may represent a means to overcome TMZ resistance and suggest the potential for prolonging survival in patients with GBM.
MATERIALS AND METHODS
Cell culture and treatment LN229 and GBM8401 human glioma cell lines were cultured in Roswell Park Memorial Institute (RPMI) 1640 cell medium supplemented with 2% fetal bovine serum, penicillin, and streptomycin at 37°C under 5% CO 2 and 95% air, as previously described in Tsai et al. (15) . We generated and sustained GBM8401 and LN229 TMZ-R sublines in our laboratory. In brief, the TMZ-R sublines were created by cyclical pulse exposure of GBM8401 and LN229 cells to a high concentration of TMZ (500 mM) for 72 h weekly. In each cycle, the surviving TMZ-R cells were collected, seeded onto 6-cm dishes, and cultivated for 2 wk. Several GBM8401 and LN229 TMZ-R clones were created after repeating the cycle for 3 mo. HepG2 cells [American Type Culture Collection (ATCC), Manassas, VA, USA] were kept in 10% fetal bovine serum DMEM and used as the positive control for MGMT expression.
RNA isolation and real-time quantitative RT-PCR
The protocols for RNA extraction, cDNA synthesis, and quantitative RT-PCR were reported in Tsai et al. (15) . The amplification and quantification of reverse transcripts were performed using an Illumina ECO Real-Time PCR System (Illumina, San Diego, CA, USA) according to the manufacturer's instructions.
The PCR primers used were as follows: for serpin family A member 1 (SERPINA1), 59-GATCAACGATTACGTGGAGAA-GG-39 (forward) and 59-CCTAAACGCTTCATCATAGGCA-39 (reverse); for ectonucleoside triphosphate diphosphohydrolase 1 (ENTPD1), 59-AGGTGCCTATGGCTGGATTAC-39 (forward) and 59-CCAAAGCTCCAAAGGTTTCCT-39 (reverse); for MGMT, 59-ACCGTTTGCGACTTGGTACTT-39 (forward) and 59-GGAG-CTTTATTTCGTGCAGACC-39 (reverse); for glyceraldehyde 3phosphate dehydrogenase, 59-CTTCATTGACCTCAACTAC-39 (forward) and 59-GCCATCCACAGTCTTCTG-39 (reverse). The quantitative gene expression was standardized to the expression of glyceraldehyde 3-phosphate dehydrogenase. For mRNA stability assays, actinomycin D (ActD; 0.2 mg/ml; MilliporeSigma, Burlington, MA, USA) was added to the culture medium.
Determination of nitrite levels in Griess assays
Nitrite levels in the supernatants were measured in colorimetric assays using Griess reagent (Thermo Fisher Scientific, Waltham, MA, USA) as previously described in Green et al. (16) . The absorbance of the samples was measured at 548 nm using a Spec-traMax 190 Microplate Reader (Molecular Devices, Sunnyvale, CA, USA), and nitrite levels were calculated with reference to a set of sodium nitrite standards.
Western blot analysis
Western blot analyses were performed using anti-g-histone family member X (g-H2A.X; Abcam, Cambridge, MA, USA), anti-cleaved poly (ADP-ribose) polymerase (PARP; Cell Signaling Technology, Danvers, MA, USA), anti-MGMT (Abcam), anti-phosphorylated (p-)p53 (Cell Signaling Technology), anti-p53 (Santa Cruz Biotechnology, Dallas, TX, USA), antip-NDRG1 (Cell Signaling Technology), anti-NDRG1 (Cell Signaling Technology), and anti-iNOS (BioLegend, San Diego, CA, USA) antibodies. b-actin (Santa Cruz Biotechnology) and anti-actinin (ACTN; Santa Cruz Biotechnology) were used as endogenous references.
Colony formation assays
Glioma cells were plated in 6-well plates at a density of 500 cells per well and cultured for 2 wk. The colonies were then fixed with methanol and stained with 0.5% crystal violet. Colonies were measured using ImageJ software (National Institutes of Health, Bethesda, MD, USA), and those larger than 0.1 mm in diameter were counted.
Cell cycle and proliferation assays
For cell cycle analysis, glioma cells were fixed in 70% ethanol at 4°C and kept overnight at 220°C, as previously described in Tsai et al. (15) . The cells were then washed twice with cold PBS and stained with propidium iodide (PI) solution (50 mg/ml PI in PBS, 1% Tween 20, and 10 mg/ml RNase A) for 30 min in the dark. The DNA content of the cells was measured using fluorescenceactivated cell sorting (BD Biosciences, San Jose, CA, USA). The experiments were independently performed twice.
Glioma cell proliferation was assayed using FITC-59-bromo-29-deoxyuridine (BrdU) flow kits according to the manufacturer's instructions (BD Biosciences). The percentage of positive glioma cells was determined using flow cytometry.
To assess cell viability, MTS assays were performed using Cell Titer 96 Aqueous One Solution Reagent (Promega, Madison, WI, USA). Briefly, cells were incubated for 2 h in RPMI 1640 cell medium (200 ml) supplemented with MTS solution (20 ml/well), after which the absorbance at 490 nm was recorded using a Molecular Devices SpectraMax 190 Microplate Reader.
Apoptosis assay
To assess the incidence of apoptosis, we used a Muse Annexin V and Dead Cell Assay Kit (Merck, Darmstadt, Germany) according to the manufacturer's instructions. Briefly, glioma cells were seeded into 6-cm dishes at a density of 3 3 10 5 cells per dish. After treatment, stained cells were detected using a Muse Cell Analyzer. The cells were categorized into 3 groups: viable (annexin V 2 and PI 2 ), apoptotic (annexin V + and PI 2 ), and necrotic (annexin V + and PI + ).
Measurement of mitochondrial membrane potential and intracellular oxygen tension
Mitochondrial membrane potential was assessed using a JC-1 MitoScreen Kit (BD Biosciences) in accordance with the manufacturer's instructions. Glioma cells were washed, resuspended in 500 ml of JC-1 working solution, and incubated for 15 min at 37°C. The stained cells were then washed twice, resuspended in 500 ml of assay buffer, and immediately examined using a BD FACSCalibur flow cytometer (BD Biosciences). We gated and evaluated only live glioma cells. We also used the hypoxiadetecting probe mono azo rhodamine (MAR; Goryo Chemical, Sapporo, Japan) to measure intracellular oxygen tension as previously described. Glioma cells treated with SNAP for 48 h were incubated in 5 mM MAR for 1 h, after which the fluorescence intensity was evaluated using a FACSCalibur Flow Cytometer (BD Biosciences).
Plasmids
Luciferase reporter plasmid, pG13-LUC, was previously described (17) . Wild-type human p53 cDNA clones encoding from cDNA library (Takara Bio, Mountain View, CA, USA) was cloned into pSG5.HA (hemagglutinin) (18) . MGMT promoter was obtained and fitted with XhoI and HindIII sites by PCR amplification, and then subcloned into the XhoI-HindIII sites of pGL3 basic vector (Promega).
Examination of MGMT promoter methylation status
Genomic DNA was extracted using the standard phenolchloroform protocol. The patterns of CpG island methylation in the MGMT promoter were determined by chemical modification of unmethylated, but not methylated, cytosines to uracil. Primers with specificity for either methylated or the modified unmethylated DNA were used for methylation-specific PCR, as previously described in Esteller et al. (19) . Samples of DNA (2 mg) were denatured with sodium hydroxide, modified with sodium bisulfite, and purified using an EZ DNA Methylation Kit (Zymo Research, Irvine, CA, USA). The primer sequences for the unmethylated reaction were 59-TTTGTGTTTTGATGTTTGTA-GGTTTTTGT-39 (forward) and 59-AACTCCACACTCTTCCA-AAAACAAAACA-39 (reverse); for the methylated reaction, the primers were 59-TTTCGACGTTCTAGGTTTTCGC-39 (forward) and 59-GCACTCTTCCGAAAACGAAACG-39 (reverse). The amplified PCR products were loaded onto 3% agarose gels, stained with ethidium bromide, and observed under UV illumination.
Global gene expression profiling
Total RNAs from parental and TMZ-R LN229 and GBM8401 cell lines were analyzed using Human OneArray Plus (Phalanx Biotech Group, Hsinchu, Taiwan). The gene expression values were determined using the Agilent Technologies (Santa Clara, CA, USA) 0.1 XDR Protocol. Fold changes were calculated as the ratio of the mean values for TMZ-R cells to the values for the parental cells.
Bioinformatics investigation of The Cancer Genome Atlas data
We mined a data set from The Cancer Genoma Atlas (TCGA) using the Gene Expression Profiling Interactive Analysis (GEPIA) online tool (http://gepia.cancer-pku.cn/) (20) . GEPIA offered customizable function analyses of the TCGA data set, including patient survival analysis, cancer and normal differential expression analyses, and gene correlation analyses.
Reporter assays
For luciferase reporter assays, LN229 and GBM8401 TMZ-R cells were seeded into 24-well plates at a density of 5 3 10 4 cells per well and incubated for 24 h. Thereafter, the cells were transfected with p53-luciferase or MGMT-luciferase in the presence or absence of SNAP (400 mM) using jetPei Transfection Reagent (Polyplus-Transfection, Illkirch-Graffenstaden, France) according to the manufacturer's instructions. The total amount of transfected DNA was made constant by adding required quantities of empty plasmid. Twenty-four hours post-transfection, luciferase activities in the transfected cell lysates were measured using a dual luciferase reporter assay system (Promega) and expressed as relative light units.
Orthotopic tumor xenografts in nude mice
We used human glioma cells carrying the luciferase gene for infrared luminance (iRL) imaging of orthotropic xenografts. All procedures were approved by the Institutional Animal Care and Use Committee of the National Defense Medical Center. Female 5-6-wk-old nude mice were purchased from the National Laboratory Animal Center. As previously described (15) , each mouse was placed in a stereotactic frame after intraperitoneal anesthetization. We then made a 5-mm midline cranial incision and created a burr hole in the right side of the skull, 2.5 mm lateral to the midline and 0.4 mm posterior to the bregma. Thereafter, 1 3 10 5 GBM8401-iRL cells in 5 ml of culture medium and Matrigel (Corning, Corning, NY, USA) were injected into the goal site 3 mm below the brain surface. To test the drug treatment in vivo, 7 d after introducing the tumor xenograft, mice with comparable tumor bioluminescence were divided to 4 groups: 1) control (PBS, intraperitoneal), 2) TMZ (50 mg/kg, i.p.), 3) SNAP (50 mg/kg, i.p.), and 4) TMZ + SNAP (2-drug, intraperitoneal). Each group was treated for 10 d. Tumor progression was examined using bioluminescence imaging with an in vivo imaging system (IVIS; Xenogen, PerkinElmer, Waltham, MA, USA) after 3, 7, and 11 d of drug treatment. All the mice were euthanized 18 d after transplantation.
Statistical analysis
We used a Student's t test or 1-way ANOVA to compare differences between the experimental and control groups. Outcomes are presented as means 6 SD or as stated. Statistical significance was set at P , 0.05.
RESULTS

Establishment of TMZ-R glioma cell lines
To investigate SNAP as a therapeutic drug for the treatment of GBM, with and without TMZ resistance, we first established TMZ-R glioma cell lines by repeatedly collecting and culturing LN229 and GBM8401 human glioma cells surviving after exposure to TMZ. The viability of the parental cells and TMZ-R cells in the presence of TMZ was evaluated using MTS assays (Fig.  1A) . The LN229 and GBM8401 TMZ-R cells showed significantly greater viability in the presence of TMZ than the parental cells. The calculated median inhibitory concentration (IC 50 ) values were 37.7 and 49.8 mM, respectively, for the parental LN229-iRL and GBM8401-iRL cells, but were 729.5 and 594.2 mM for the corresponding TMZ-R lines. There were no apparent morphologic differences between the parental and TMZ-R cells, which had similar polygonal or round shapes ( Fig. 1B ). Because the cytotoxicity of TMZ to glioma cells is reportedly abolished by overexpression of MGMT (2), which mediates repair of DNA damage caused by TMZ, we used Western blotting and real-time PCR to check the levels of MGMT protein and mRNA in the GBM cells (Fig. 1C, D) . The results demonstrate that both MGMT protein and mRNA are significantly overexpressed in LN229 and GBM8401 TMZ-R cells.
SNAP inhibits the growth and proliferation of GBM cells
To assess the inhibitory effect of SNAP on glioma cell survival, we evaluated the viability of parental and TMZ-R glioma cells in the presence of selected concentrations of SNAP for 24, 48, and 72 h by MTS assay. Glioma cell numbers were all significantly decreased after treatment with SNAP for 48 or 72 h. Glioma cells were treated for 48 h to determine the IC 50 for SNAP; the IC 50 of parental LN229-iRL cell was 93.05 mM, whereas the IC 50 of TMZ-R line was 84.76 mM. The IC 50 of parental GBM8401-iRL cell was 99.95 mM, whereas the IC 50 of TMZ-R line was 133.97 mM. By contrast, low concentrations of SNAP induced cell growth at 24 h ( Fig. 2A) . Cell counting method consistently found similar dosedependently inhibitory effect on GBM cell growth (Supplemental Fig. S1A ). Importantly, a normal glial cell line, SVG p12, has a higher IC 50 than GBM cells (Supplemental Fig. S1B ). Because SNAP is an NO donor, we performed Griess assays to examine the nitrite levels in the 4 groups of GBM cells (Fig. 2B) . In all 4 cell types, SNAP elicited concentration-dependent increases in the abundance of nitrite. However, SNAP produced different levels of nitrite level in the isogenic parental and TMZ-R cell lines that might be attributed to the discrimination between the isogenic parental and TMZ-R cell lines. In addition, flow cytometric analysis revealed that treatment with SNAP for 48 h led to reduced G 1 phase arrest, which was accompanied by increased sub-G 1 phase and S-phase populations (Fig. 2C ). Assessment of cell proliferation based on BrdU incorporation showed that the M2 values for both control and TMZ-R cells were concentration-dependently lowered by SNAP. Thus, although TMZ-R GBM cells exhibit a higher proliferation rate than parental glioma cells, it appears that SNAP causes proliferation arrest in both parental and TMZ-R GBM cells ( Fig. 2D ).
SNAP reduces MGMT expression and increases apoptosis and expression of DNA damage markers in TMZ-R cells
Because SNAP concentration-dependently increased the sub-G 1 cell fraction, we used 7-aminoactinomycin (7-AAD) and annexin V cytometry to investigate its effect on the incidence of apoptosis (Fig. 3A) . We found that SNAP induced early-and late-stage apoptosis and that the effect was concentration dependent. Moreover, greater induction of early-stage apoptosis by SNAP was seen in TMZ-R than in the parental GBM cells. In addition to disrupting mitochondrial membrane potential, which is a distinct feature of the early stages of apoptosis, NO has been shown to induce mitochondrial membrane permeabilization and release of caspases, leading to eventual cell death (21) . When we examined the mitochondrial membrane potential using flow cytometric analysis of JC-1 staining, we detected concentration-dependent increases in the proportion of apoptotic cells with elevated cytoplasmic JC-1 monomer in all 4 SNAP-treated GBM cell types, indicating depolarization of the mitochondrial membrane ( Fig. 3B ).
We also tested whether SNAP affects HIF-1 activity because earlier reports found NO had a stabilizing effect on HIF-1 (22) . The intracellular HIF-1 accumulation was evaluated using a hypoxic marker, an MAR. Increased MAR fluorescence confirmed that SNAP concentrationdependently increased intracellular hypoxia in both parental and TMZ-R GBM cells (Fig. 3C, D) .
SNAP and TMZ reduce growth of TMZ-R GBM cells
Upon investigation of the effect of SNAP on the proteins involved in DNA damage, apoptosis, and MGMT stability in parental and TMZ-R GBM cells, we first observed increases in the levels of g-H2A.X, a marker of DNA double-strand breaks, and cleaved PARP and cytochrome c, 2 apoptosis-related proteins, as well as p-p53 and p-NDRG1. Moreover, levels of these proteins were enhanced to a greater degree in TMZ-R glioma cells than in the parental cells ( Fig. 4A) . Notably, SNAP decreased MGMT levels in TMZ-R GBM cells. iNOS has been linked to tumorigenicity in several cancers, including GBM (23), and it has been suggested that inhibiting iNOS could potentially suppress GBM. We observed that SNAP concentration-dependently deceased iNOS levels in all 4 cell types (Fig. 4A) . Because it appears that SNAP may down-regulate MGMT expression in TMZ-R GBM cells (Fig. 4A ), we next examined whether SNAP increased the TMZ sensitivity of TMZ-R GBM cells (Fig. 4B ). We treated LN229 and GBM8401 TMZ-R cells with SNAP for 48 h followed by treatment with TMZ for a further 24 h, after which cell viability was assayed. Results of MTS assays showed the dual therapy significantly inhibited TMZ-R cell growth (Fig. 4B ). Assessment of molecular markers showed that SNAP was predominantly responsible for observed increases in g-H2A.X levels, cleaved PARP, total p53, and p-p53 ( Fig. 4C) , but there was a reduction of MGMT attributable to the combination of SNAP plus TMZ. We further investigated the efficacy of combined treatment with SNAP and TMZ in colony formation assays. Both SNAP and TMZ alone inhibited colony formation by glioma cells, but combined therapy further repressed colony formation by TMZ-R glioma cells ( Fig. 5A, B) . We also tested the efficacy of SNAP and TMZ in vivo by transplanting intracranial orthotropic GBM8401 (+iRL) TMZ-R xenografts into nude mice. Seven days after intraperitoneal injections from d 0 to 11 (Fig. 5C ). Measurements of tumor growth using IVIS imaging at the indicated time points showed that the combined therapy inhibited GBM8401 TMZ-R tumor growth to a significantly greater degree than either TMZ or SNAP alone (Fig. 5D, E) . 
Mechanism by which SNAP affects p53 and MGMT in TMZ-R GBM cells
Because we observed that SNAP increased p53 and NDRG levels while decreasing MGMT levels (Fig. 4A) , we tested the effect of SNAP on the p53, NDRG1, and MGMT protein stability in TMZ-R GBM cells using cycloheximide (CHX) chase assays (Fig. 6A, B) . SNAP increase the stability of p53 but decreased the stability of MGMT and p-NDRG1 in both TMZ-R cell lines. We then investigated 1 1.1 1.5 0.9 1.2 1.3 1.0   1.0 1.1 1.1 1.2 0.8 0 1.0 1.2 1.2 1.2 1.1 0.9 0.8   1.0 1.3 1.4 1.4 1.1 1.3 0.9 Transfectants were grown in the presence of the indicated concentration of SNAP, after which luciferase activities in the extracts from the transfectants were determined. Symbols depict means 6 SD of 3 independent experiments. E ) TMZ-R LN229 and GBM8401 cells were transiently transfected with the MGMT-LUC reporter gene (0.025 mg) with the indicated amount of pSG5.HA.p53 expression vector. Luciferase activity was measured in relative light units (RLU). Symbols indicate means 6 SD of 3 independent experiments. F, G) Analyses of MGMT (F ) and p53 (G) mRNA stability in TMZ-R LN229 and GBM8401 cells. Cells were exposed to the transcription inhibitor ActD, after which total RNA was collected at indicated times (means 6 SD; n = 3).
whether SNAP alters the methylation status of the MGMT promoter in parental and TMZ-R GBM cells. Prior to SNAP treatment, the levels of MGMT methylation were lower in TMZ-R GBM cells than in the parental cells ( Fig.  6C ). SNAP further decreased methylation of the MGMT promoter in TMZ-R GBM cells. Luciferase reporter assays revealed that SNAP had little effect on MGMT or p53 promoter activity, and there was no significant difference between p53 and MGMT promoter-driven luciferase activity at any SNAP dosage (Fig. 6D ). In addition, p53 had no effect on MGMT promoter activity (Fig. 6E) . We then used ActD to test whether SNAP modulates the stability of MGMT and p53 mRNAs. Our data showed that MGMT mRNA was less stable than p53 mRNA and that SNAP increased the stability of MGMT mRNA in GBM8401 TMZ-R cells but not in LN229 TMZ-R cells (Fig. 6F, G) . On the other hand, SNAP did not stabilize p53 mRNAs, except in GBM8401 TMZ-R cells treated for 48 h with ActD. 
SNAP induced differential gene expression in TMZ-R GBM cells
Using a gene microarray with parental and TMZ-R glioma cells, we selected the most up-or down-regulated genes in TMZ-R cells (Fig. 7A) . After review of the literature, we checked whether SNAP altered the mRNA expression of 2 potential glioma oncogenes, SERPINA1 (22) and ENTPD1 (25) . By mining the TCGA data set using GEPIA (20) , we confirmed that both SERPINA1 and ENTPD1 were highly overexpressed in gliomas. In addition, there were also adverse predictors for glioma survival (Fig. 7B ). As shown in Fig. 7C ,D, SNAP treatment suppressed expression of SER-PINA1 and ENTPD1 mRNAs in TMZ-R glioma cells, which implies these 2 proteins are likely downstream SNAP targets.
DISCUSSION
Administration of TMZ to patients with GBM increases their survival time, but the benefit of TMZ is limited by up-regulation of MGMT, which decreases the susceptibility of GBM to TMZ. To test the potential efficacy of SNAP as a novel agent for GBM treatment, we examined its effects on TMZ-R GBM clones in vitro and in vivo. NO regulated mitochondria function to induce apoptosis (21, 26) . Our data demonstrated that SNAP administration induced dose-dependent nitrite production. Moreover, SNAP disrupted mitochondrial function, increased cellular hypoxia, induced apoptosis, and inhibited the growth of GBM clones. Treatment with SNAP or a combination of TMZ plus SNAP led to resensitization of TMZ-R cells to TMZ chemotherapy through down-regulation of MGMT. Furthermore, combining TMZ and SNAP further enhanced the beneficial effects of the 2 drugs in vitro and in vivo. Regarding mechanism, SNAP not only decreased methylation of the MGMT promoter; it also decreased the stability of p-NDRG1. We therefore propose that multiple pathways lead to the increased sensitivity of the tested TMZ-R GBM cells to TMZ.
The tumor suppressor p53 acts as a critical transcriptional factor whose downstream target genes mediate cellular senescence, apoptosis, and growth arrest. The abundance of p53 in normal cells is generally very low because of its short half-life. The stability and function of p53 are critically regulated by post-translational modifications, such as acetylation, phosphorylation, methylation, and ubiquitination (27) . The accumulation of p53 could prevent tumor formation by inducing apoptosis related to DNA injury or other conditions inducing cellular stress. For that reason, up-regulation of p53 is often proposed as an anticancer strategy.
Exogenous NO donors reportedly provoke p53 accumulation in multiple cancer cell lines, including U2OS human osteosarcoma cells (28) , neuroblastoma cells (29) , and ovarian cancer cells (10) . Although the mechanism by which NO induces p53 activation is not clear, evidence from several studies provides potential explanations. Wang et al. (30) reported that in various cell lines NO down-regulates levels of mouse double minute 2 homolog (Mdm2), an essential protein mediating p53 degradation by forcing its ubiquitination. Schneiderhan et al. (31) reported that after NO treatment, cells exhibited major nuclear accumulation of p53 in tight correlation with its phosphorylation on Ser15. In addition, Kitagaki et al. (32) reported that the NO prodrug JS-K blocks the ubiquitinactivating enzyme E1, which catalyzes the initial step in the ubiquitin-degradation system.
The status and behavior of p53 in LN229 cells is an interesting issue in this study because the ATCC lists LN229 as a tumor protein p53 mutant cell line. Van Meir et al. (31) reported p53 gene mutation at exons 5-8 in the LN229 cell line, but LN229 still encompasses functional p53 protein activity proved by trans-activation activity using the PG13CAT reporter. Besides, LN229 had been used as a functional p53 group to test the celecoxib cytotoxic effect by Kang et al. (33) . However, we could not exclude the possibility of ongoing accumulation of tumor protein p53 mutations that are well documented to occur in cancer cell lines over time (35) . Experiments to verify whether apoptosis provoked by SNAP depends on the existence of functional p53 are required in the future.
NO also provokes apoptosis in lung cancer cells by inhibiting antiapoptotic proteins (36) , and in ovarian cancer cells by down-regulating the transcription repressor yinyang-1 to activate Fas expression (37) . Other effects of NO are reviewed in Singh and Gupta (8) . In the present study, increasing the SNAP concentration was sufficient to provoke apoptosis as a result of increases in the sub-G 1 cell fraction, loss of mitochondrial membrane potential, translocation of cytochrome c, and increases in cleaved PARP. These results suggest that the SNAP-induced up-regulation of p53 in GBM cells is associated with post-translational modifications that increase p53 stability. Further studies will be needed to determine the precise mechanism.
MGMT enzymatic activity disrupts the therapeutic response to TMZ in patients with GBM and reduces survival time. The latest meta-analysis, which covered 4097 subjects, concluded that higher MGMT methylation status in patients with GBM correlated significantly with longer general survival (38) . Thus, MGMT silencing or depletion is a potential strategy to augment the beneficial effects of chemotherapy with alkylating agents. The induction of p53 could silence MGMT gene in human tumor cells, which would enhance sensitivity to TMZ (39) . It has also been reported that drugs such as levetiracetam (40) and in combination with TMZ sensitize GBM cells to TMZ via p53-mediated MGMT repression. In this study, down-regulation of MGMT and up-regulation of p53 were observed in 2 TMZ-R GBM cell lines treated with SNAP. However, we detected no direct effect of p53 on expression of MGMT mRNA or protein, even when overexpressed (Fig. 6E ). Harris et al. (42) reported a related finding that there are no p53 binding sites in the MGMT promoter. Both p53 and hypoxia are upstream regulators of NDRG1 and p-NDRG1, which may act to stabilize MGMT. NDRG1 protein could bind to MGMT protein and stabilize the MGMT protein to prevent degradation (5) . Fig. 4A shows that SNAP dose-dependently increases p-NDRG1 protein expression. The possible mechanism is that SNAP activates the upstream regulators of NDRG1 and p-NDRG1, including p53 ( Fig. 4A ) and hypoxia (Fig. 3C, D) . In contrast to Fig. 6A , p-NDRG1 protein stability was decreased in time course-treated protein synthesis inhibitor CHX because of a dose-dependent reverse of the increase of p-NDRG1, suggesting that the indirect repression mechanism of instability of p-NDRG1 protein provoked by SNAP needs further investigation in the future.
In patients with GBM, expression of iNOS mRNA is higher within the tumor itself and in the peritumor region than in adjacent normal brain tissue (43) . iNOS is linked to malignancy and poor survival of several cancers, including breast cancer (44) , melanoma (45) , and GBM (46) . For that reason, iNOS silencing has been proposed as a potential treatment target. Eyler et al. (46) found that glioma stem cells could be distinguished from nonstem glioma cells based on their high iNOS expression, which promoted cell growth and tumorigenicity. They also showed that iNOS silencing inhibited tumor growth in vitro and in vivo (46) . Furthermore, elevated iNOS was also associated with radio resistance in the A172, U87, and U373 glioma cell lines (47, 48) . Here, we found that a higher concentration of SNAP clearly inhibited iNOS expression in both parental and TMZ-R GBM cells (Fig. 4A ). That finding supports the idea that SNAP inhibits GBM tumorigenicity in part by down-regulating iNOS production. Chang et al. (49) reported that SNAP down-regulates iNOS gene expression in hepatocytes, evidenced by decreased iNOS transcription rate and iNOS mRNA expression. Lu et al. (50) also found that SNAP suppresses iNOS gene expression and mRNA stability in macrophage. These data identify that the regulation of iNOS gene expression is negative feedback by NO.
Limitation of this study included that the current study did not yet present the survival curve. The survival curve would be strong evidence for the efficacy of combined TMZ and SNAP in TMZ-R glioma models. However, tumor-inoculated mice suffer from lethargy, anorexia, dehydration, weight loss, pain, and other sign of obvious stress as tumors grow day by day. Therefore, this study utilized IVIS to reduce the number of animals as well as improve their welfare during the animal study and to provide real-time and noninvasive observation of tumor growth of each subject. Downsizing tumor is theoretically helpful for prolonging survival time. Future study will further clarify the survival curve for the efficacy of combined TMZ and SNAP in TMZ-R glioma models.
SNAP has quite a strong effect of inhibiting cell growth of tumor cells. To make this a potential treatment for glioblastoma, the drug effect on normal cells in the CNS was further investigated in human normal glial cells, SVG p12, as normal control. SNAP dose-dependently inhibits the growth of SVG p12 cells. Importantly, the IC 50 of SVG p12 is 195 mM, which is much higher than the IC 50 (48.99 mM) of LN229 and GBM8401 GBM cells, supporting that SNAP has a potential for glioblastoma treatment.
CONCLUSIONS
We found that SNAP is a potential antiglioma drug that exerts intriguing concentration-dependent effects leading to apoptosis, up-regulation of p53, and down-regulation of p-NDRG-1, iNOS, and MGMT. Combined SNAP and TMZ therapies overcome the TMZ resistance in GBM cells and open new possibilities for glioma management.
